Amlexanox
Aphthasol
Amlexanox (Aphthasol) is a metabolic & fat loss research compound. Inhibits TBK1 and IKK-epsilon, two kinases that drive the chronic low-grade inflammation of obesity and suppress energy expenditure. Blocking them raises cAMP and increases metabolic rate in fat tissue.
Amlexanox quick facts
| Reported research dose | 50mg-100mg |
| Route | Oral |
| Frequency | Not established — no dosing protocol has been characterized |
| Half-life | ~3.5 hours |
| Forms | Oral |
| Evidence level | A small pilot in obese type-2 diabetics improved HbA1c and hepatic fat — in responders only |
Approved as a paste for mouth ulcers; the metabolic use is entirely repurposed. The pilot trial is the interesting bit and its own caveat — the benefit appeared in a responder subgroup, not across the board, which usually means an effect that won't replicate cleanly. Genuinely early.
How Amlexanox works
Inhibits TBK1 and IKK-epsilon, two kinases that drive the chronic low-grade inflammation of obesity and suppress energy expenditure. Blocking them raises cAMP and increases metabolic rate in fat tissue.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Amlexanox
Buy Amlexanox at Disguised Alpha →The evidence for Amlexanox
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved — as a 5% oral paste for aphthous ulcers, which has nothing to do with why it appears here. That approval establishes human safety by a topical route only.
- A phase 2 trial in obese patients with type 2 diabetes tested it orally and reported improved glycemic control and reduced hepatic steatosis — but only in a responder subgroup, roughly half the participants, distinguished by their inflammatory profile at baseline.
- A responder-only result in a small trial is a hypothesis about who it works for, not a demonstration that it works.
📊 Correlative data
- Almost no metabolic real-world use; it remains largely a research compound outside its dental indication. The trial identified elevated baseline inflammatory markers as the responder signature, which is at least a testable prediction.
🧪 Theoretical / extrapolated
- Inhibits TBK1 and IKK-epsilon, two kinases induced by obesity-related inflammation that suppress energy expenditure by degrading cAMP signaling in fat tissue.
- The interesting claim is directional: these kinases are part of a counter-regulatory brake that switches on with chronic inflammation, so inhibiting them releases a brake rather than pressing an accelerator.
- That explains the responder subgroup precisely — if the brake is not engaged, there is nothing to release. It is one of the few compounds here whose mechanism predicts its own non-responders.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Amlexanox actually does
Amlexanox inhibits two kinases — TBK1 and IKK-epsilon — and the reason that produces a metabolic effect is one of the most satisfying mechanism chains in this catalog, because it ends at a specific enzyme in the fat cell.
The chain, one step at a time. Obesity produces a chronic inflammatory state involving NF-kappaB signaling, and one consequence is persistent elevation of the non-canonical IkappaB kinases IKK-epsilon and TBK1 in white adipose tissue. Those kinases phosphorylate and activate PDE3B, the major adipocyte phosphodiesterase. PDE3B degrades cyclic AMP. Cyclic AMP is the second messenger every catecholamine signal in the fat cell runs through. So chronic inflammation installs an enzyme that drains the signal before it can act Mowers 2013.
That is catecholamine resistance, and it was demonstrated in both directions. Treating 3T3-L1 adipocytes with specific inhibitors of these kinases restored beta-adrenergic signaling and lipolysis that had been blunted by TNF-alpha and poly(I:C). Overexpressing the kinases did the reverse: reduced Ucp1 induction, reduced lipolysis, reduced cyclic AMP, and reduced phosphorylation of hormone-sensitive lipase in response to isoproterenol or forskolin Mowers 2013.
And then the in-vivo experiment that ties this page to another one in the same Vault. Treating obese mice with amlexanox reversed obesity-induced catecholamine resistance and restored PKA signaling in response to injection of a beta-3 adrenergic agonist Mowers 2013. Read that carefully: the published mechanism of this compound is that it restores responsiveness to exactly the class of drug mirabegron belongs to. Nobody has run that combination in a person, and it is the most concrete stacking hypothesis in this cohort.
Why this is a brake release rather than a stimulant, and why that predicts non-responders. The kinases are induced by chronic inflammation; inhibiting them restores a signal that was already being sent. In a person whose adipose tissue is not inflamed there is no brake engaged, so there is nothing to release. This is one of very few compounds whose mechanism predicts its own non-responders before any trial is run, and it makes the baseline inflammatory state a selection variable rather than an afterthought.
The kinases have day jobs, which is where the trouble starts. TBK1 and IKK-epsilon are innate-immune kinases — they sit downstream of nucleic-acid sensing and drive interferon responses. Inhibiting them for a metabolic purpose is inhibiting an antiviral pathway as a side effect, not as a coincidence.
Cell, rodent, human — and where it stops
Step one, cells. 3T3-L1 adipocytes, inflammatory stimuli, kinase inhibitors and kinase overexpression, with cyclic AMP, lipolysis, Ucp1 induction and hormone-sensitive lipase phosphorylation as readouts Mowers 2013.
Step two, mice, in four separate disease models. Amlexanox in obese mice reversed catecholamine resistance Mowers 2013. Inhibiting the IKK-epsilon pathway improved fat deposition in the liver, reduced subcutaneous fat inflammation and improved hepatic gluconeogenesis in obesity Xiao 2022. The inhibitor improved dyslipidemia and prevented atherosclerosis Zhao 2022. And in a MASH model it acted with effects on bile acid metabolism and the microbiome You 2025, in a literature where the roles of IkappaB kinases and TBK1 in hepatic lipid metabolism are established Huh 2021.
Step three, humans — and this page has to be careful, because what is on the card is not what the resolved literature shows. Amlexanox's approved human use is a 5% oral paste for aphthous ulcers, which establishes human tolerability by a topical mucosal route and by no other. The card above refers to a phase 2 trial in obese adults with type 2 diabetes reporting benefit in a responder subgroup. No such trial was resolvable among the sources read for this page, and the review of IKK-epsilon in metabolic disease that was read summarizes structure, physiology, pathology and small-molecule inhibitors rather than a completed human trial Xiao 2022. This page therefore does not cite a human metabolic trial and does not rest on one; the discrepancy has been reported rather than quietly resolved.
Step four, the result that runs the other way, and it is recent. In a dextran-sulfate-sodium model of inflammatory bowel disease, amlexanox's targeted inhibition of TBK1 regulated immune cell function in a way that exacerbated the colitis Hui 2024. That is the innate-immune day job showing up as harm in a tissue the metabolic story never mentions, and it belongs next to every claim about anti-inflammatory benefit.
The obstacles. (1) The route with human safety data is topical mucosal; the metabolic use is systemic and oral. (2) Every metabolic efficacy result above is rodent. (3) The mechanism predicts responders and non-responders, which means an unstratified trial is expected to dilute its own effect — and no published human study stratifies by baseline adipose inflammation. (4) The same target inhibition worsened experimental colitis Hui 2024, so the direction of the immune effect is tissue-dependent.
Amlexanox pharmacokinetics — how much of it actually gets in
The card says about 3.5 hours. Take that seriously, because for a kinase inhibitor a short half-life is a dosing-schedule problem, not a footnote.
What the molecule is, chemically. Amlexanox is a small heterocyclic carboxylic acid, not a peptide. At physiological pH that carboxyl group is ionized, which means high plasma protein binding, limited passive entry into cells, and a distribution volume closer to extracellular water than to total body water. Clearance for a molecule of this class runs through glucuronidation and renal elimination of the conjugate rather than through extensive cytochrome oxidation — which is why an acid like this generally has fewer CYP interactions than its size would suggest and more sensitivity to renal function.
The oral barrier is not the problem here, and that is worth saying because it is unusual in this cohort. Unlike every peptide on the neighboring pages, this compound is not destroyed by pepsin or brush-border aminopeptidases. An ionized acid is absorbed less efficiently than a neutral molecule and is subject to first-pass hepatic conjugation, but oral bioavailability is a real number rather than a rounding error. There is no injectable comparator in human use, because there has never been a systemic human product.
The arithmetic of a 3.5-hour half-life. Steady state arrives within about 18 hours — four to five half-lives — so unlike a monoclonal antibody or a 50-hour small molecule, this drug tells you what it is going to do within a day. The cost is coverage: with a 3.5-hour half-life, a once-daily dose leaves the kinases uninhibited for most of the 24 hours. If the mechanism is relief of a continuously applied brake Mowers 2013, then intermittent inhibition allows the brake to re-engage between doses, and divided dosing is a mechanistic requirement rather than a preference. Every rodent experiment above dosed daily in animals whose metabolic rate and clearance are far faster than a human's, which is the usual reason a rodent schedule does not transfer.
And the route mismatch, stated plainly. The approved presentation is a 5% paste held against a mucosal ulcer. That produces a very high local concentration and negligible systemic exposure. Human tolerability of the approved product therefore says almost nothing about the systemic exposure the metabolic use requires, and conflating the two is the central error made about this compound.
What would have to be true, and how you would know it was not
Three predictions with markers and windows. The first is the responder test the mechanism demands; the third argues against use in a specific group.
1. Only inflamed people should respond, so measure the inflammation first. The mechanism is release of an inflammation-installed brake on cyclic AMP signaling Mowers 2013Xiao 2022. Prediction: baseline hs-CRP and TNF-alpha stratify the response — a person in the lower half of the inflammatory range shows no metabolic movement at all, because there is no brake engaged. This is falsifiable in the most useful direction: if lean, non-inflamed people respond, the brake-release model is wrong and the compound is doing something else.
2. Hepatic markers should move before body composition does. Three separate rodent lines point at the liver: improved hepatic fat deposition and gluconeogenesis Xiao 2022, established roles of these kinases in hepatic lipid metabolism Huh 2021, and a MASH model with bile-acid and microbiome effects You 2025. Prediction: a CMP with transaminases and HbA1c at baseline and at 12 weeks move before any change in weight, with ALT the most likely first mover in a person with fatty liver. If nothing hepatic moves, the mechanism is not engaging.
3. Against the product: this should be avoided by anyone with inflammatory bowel disease, and the prediction is specific. Amlexanox-mediated TBK1 inhibition exacerbated DSS-induced colitis by altering immune cell function Hui 2024. Prediction: in a person with quiescent inflammatory bowel disease, systemic TBK1 inhibition raises the probability of a flare, and the observable is stool frequency and blood rather than a blood marker — with hs-CRP as the lagging confirmation. The thing that will fool you is attributing early loose stools to a gastrointestinal side effect of a new drug rather than to the disease process the drug is acting on. That distinction takes weeks to become obvious and the mechanism says which way to bet.
What nobody has tested yet
Four experiments, and the first would settle the compound's whole case.
Whether the combination with a beta-3 agonist does in a person what it did in a mouse. Amlexanox restored PKA signaling in response to a beta-3 agonist in obese mice Mowers 2013, and a beta-3 agonist is an approved, available drug. Pairing them and measuring lipolytic response, resting energy expenditure and insulin sensitivity is a straightforward human study with a strong mechanistic rationale, and nobody has run it.
Whether the responder signature is measurable in advance. The brake-release logic predicts it should be. Nobody has published a prospective human study stratifying by adipose tissue inflammation, and until somebody does, every unstratified trial of this compound is diluting its own effect by design.
What happens to the antiviral response. TBK1 and IKK-epsilon are interferon-pathway kinases, and inhibiting them altered immune cell function enough to worsen experimental colitis Hui 2024. Whether chronic systemic inhibition measurably impairs innate antiviral responses in people has not been asked, and it is the safety question a long course would raise.
Whether the microbiome effect is a mechanism or a consequence. The MASH work implicates bile acid metabolism and the microbiome You 2025. A germ-free or antibiotic-treated arm would distinguish a drug that works through the microbiome from one that merely changes it, and that experiment has not been reported.
Amlexanox — its own safety story, not its class's
The safety story here is a route mismatch and an immune pathway, and neither is captured by the approval this compound carries.
The approval is for a paste and the use is not. Amlexanox is approved as a 5% oral paste applied to aphthous ulcers. That establishes local mucosal tolerability. It establishes nothing about daily systemic exposure over months, which is what the metabolic use requires. Treating an approval as transferable across routes is the single most common reasoning error in the repurposing space, and this compound is its clearest example.
The immune direction is not uniformly favorable. The compound's targeted TBK1 inhibition exacerbated DSS-induced inflammatory bowel disease through effects on immune cell function Hui 2024. Anyone with an inflammatory bowel condition, or with a family history of one, is in a group where the mechanism has a published reason to make things worse.
The kinases being inhibited are antiviral kinases. TBK1 and IKK-epsilon sit in the innate nucleic-acid-sensing pathway that drives type I interferon. The metabolic literature treats them as inflammation kinases Xiao 2022Huh 2021 because that is the context it studies them in; the same molecules are how a cell recognizes viral nucleic acid. Chronic inhibition is therefore a chronic partial suppression of that arm, and no human dataset quantifies it.
The honest position on the human metabolic evidence. The responder-subgroup result that makes this compound interesting could not be resolved in the primary literature searched for this page, and the review that was read describes preclinical work and small-molecule inhibitors rather than a completed human trial Xiao 2022. A responder-only effect in a small trial is a hypothesis about who might benefit, not a demonstration that anybody does — and a hypothesis whose source cannot be pinned down should be treated as even weaker than that until it is.
Sources read for this page
- Mowers J, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKepsilon and TBK1. eLife 2013 · PMID 24368730
- Xiao QA, et al. Role of IKKepsilon in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology. Frontiers in Pharmacology 2022 · PMID 35662709
- Zhao P, et al. The TBK1/IKKepsilon inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis. JCI Insight 2022 · PMID 35917178
- Huh JY, et al. Roles of IkappaB kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease. Experimental and Molecular Medicine 2021 · PMID 34848839
- You W, et al. Unlocking therapeutic potential of amlexanox in MASH with insights into bile acid metabolism and microbiome. NPJ Gut and Liver 2025 · PMID 40519640
- Hui L, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clinical and Experimental Immunology 2024 · PMID 39248363
Amlexanox — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Beta-2 agonists (clenbuterol, albuterol) and central stimulants (tesofensine) share one predicted problem: cardiac load. Raised heart rate, palpitations, tremor and insomnia are the mechanism showing up, not an idiosyncratic reaction.
- Beta-2 agonists drive potassium into cells, so hypokalemia is predicted — and low potassium is itself arrhythmogenic, which is how a stimulant side effect becomes a cardiac one.
- Clenbuterol's half-life is long (well over a day in humans), so it accumulates across daily dosing. The dose that felt fine on day one is not the exposure you have on day five.
- Beta-2 receptors downregulate within around two weeks — the thermogenic effect fades while the cardiac effect persists longer. That is the worst possible combination and it is why escalating the dose to chase the original effect is the dangerous move.
What has actually been reported
- Cardiac hypertrophy is documented in animal models at sustained high doses. Human data comes largely from poisoning case reports — tachycardia, tremor, hypokalemia, and arrhythmia.
- Tesofensine raised blood pressure and heart rate in trials, which is part of why its development for obesity stalled.
How to reduce the risk
Same mechanism as the prediction.
- Take a resting heart rate every morning. It moves before anything else does and it is a better early signal than any quarterly panel.
- Potassium and magnesium intake matter here specifically because of the intracellular shift — this is one of the few places a supplement addresses the actual mechanism rather than a vague deficiency.
- Do not escalate to recover a faded effect. The fade is receptor downregulation, and the answer is a break, not more.
What it does to your bloodwork
A fact about the assay.
- Potassium and magnesium (a CMP covers potassium). Blood pressure and resting heart rate are the real monitoring and they are free.
Don't run this if
- You have any arrhythmia, structural heart disease, or uncontrolled hypertension.
- You are already taking another stimulant, including high-dose caffeine — the cardiac effects are additive and people do not count coffee.
The honest unknown
- Whether the cardiac hypertrophy seen in animals occurs at the doses and durations used in humans is not established, and it would be difficult to study ethically.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Amlexanox — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Amlexanox moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Amlexanox in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Amlexanox
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Amlexanox — frequently asked questions
What is Amlexanox?
Amlexanox (Aphthasol) is a metabolic & fat loss research compound. Inhibits TBK1 and IKK-epsilon, two kinases that drive the chronic low-grade inflammation of obesity and suppress energy expenditure. Blocking them raises cAMP and increases metabolic rate in fat tissue.
Is the full Amlexanox protocol on this page?
The reported research dose is on this page, along with how Amlexanox works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Amlexanox?
Amlexanox has an approximate half-life of ~3.5 hours, which is part of what determines how often it's dosed.
What's the evidence behind Amlexanox?
Current evidence level: A small pilot in obese type-2 diabetics improved HbA1c and hepatic fat — in responders only. Amlexanox is offered for research purposes only and is not an approved medicine.
What Amlexanox is used for
Amlexanox appears under 1 goal in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.